General Information of Drug (ID: DMQSA7H)

Drug Name
Interferon beta 1a Drug Info
Synonyms Aerosolised interferon beta 1a; AZD-9412; Inhaled interferon beta 1a; SNG-001
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Phase 2 [1]
Therapeutic Class
Respiratory Agents
Cross-matching ID
TTD Drug ID
DMQSA7H

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Interferon-beta (IFNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PEGylated IFN beta 1-a DMRH0D5 Type-2 diabetes 5A11 Approved [2]
PLEGRIDY DMAKXW9 Multiple sclerosis 8A40 Approved [3]
Interferon beta-1a DM1A6RV Multiple sclerosis 8A40 Approved [4]
FP-1201 DM823WQ Acute lung injury NB32.3 Phase 3 [5]
NU-100 DMA16IL Multiple sclerosis 8A40 Phase 3 [6]
Biferonex DM57B9J Multiple sclerosis 8A40 Phase 3 [7]
AZ-01, PEGylated interferon-beta DMHFUJT Multiple sclerosis 8A40 Phase 2 [6]
PF-06823859 DM8C1H4 Dermatomycosis EA60 Phase 2 [8]
ARX-424 DM4CZ2Y Multiple sclerosis 8A40 Phase 1 [6]
Gene therapy, IFN-b DMJP83V Glioblastoma multiforme 2A00.0 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon-beta (IFNB1) TT4TZ8J IFNB_HUMAN Modulator [1]

References

1 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
2 Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107.
6 PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
7 Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65.